Subsequent studies in the cohorts of patients with PD-L1-positive advanced SCCA [86] and advanced CRC [87] showed acceptable safety and the promising anti-tumor efficacy of pembrolizumab, warranting further investigations. This evidence concerns the gene CD274 and neoplasm.